ABBVIE INC.

ISIN: US00287Y1091 WKN: 00287Y109 Asset Class: Stock



Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

	Financial figures, Fiscal year: from 01.01. to 31.12.	
2004		

	20	21	202	20	201	19
Financial figures	Assets Liabilities and equity		Assets Liabilities and equity		Assets Liabilities and equity	
Current assets	27,928,000,000		24,173,000,000		49,519,000,000	
Common stock capital		18,000,000		18,000,000		18,000,000
Fixed assets	118,601,000,000		126,392,000,000		39,596,000,000	
Equity capital of a company		15,436,000,000		13,097,000,000		-8,172,000,000
Cash and cash equivalents	9,746,000,000		8,449,000,000		39,924,000,000	
Accrued liabilities		3,153,000,000		3,413,000,000		2,949,000,000
Other assets	-		-		-	
Current liabilities		35,194,000,000		28,661,000,000		15,585,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		95,899,000,000		108,807,000,000		81,702,000,000
Different income		-		-		-
Other liabilities		18,865,000,000		17,682,000,000		11,625,000,000
Total assets	146,529,000,000	146,529,000,000	150,565,000,000	150,565,000,000	89,115,000,000	89,115,000,000

Balance notes

	2021	2020	2019
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	50,000	47,000	30,000
Equity ratio	10.55%	8.71%	-9.17%
Debt-equity ratio	847.55%	1,047.77%	-1,190.49%

0	Ħ	h	۵	r

	2021	2020	2019
Tax Expense Rate	11.09%	-36.02%	6.46%

ABBVIE INC.

ISIN: US00287Y1091 WKN: 00287Y109 Asset Class: Stock

Income statement			
	2021	2020	2019
Turnover	56,197,000,000	45,804,000,000	33,266,000,000
Net income	11,468,000,000	4,556,000,000	7,842,000,000
EBIT	14,853,875,400	5,539,697,800	9,613,203,600
Operating income before taxes	12,989,000,000	3,398,000,000	8,426,000,000
Cash Flow	22,777,000,000	17,588,000,000	13,324,000,000
Net interest income	-2,410,000,000	-2,345,000,000	-1,540,000,000
Research and development expenses	6,980,000,000	6,173,000,000	5,377,000,000
Income taxes	1,440,000,000	-1,224,000,000	544,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	1,084,153	940,054	1,069,613

Board of Directors

Members of Manag	gement Board
Dahart Alpara	Member of Board of Directors
Robert Alpern	
Brett Hart	Member of Board of Directors
Edward Rapp	Member of Board of Directors
Frederick Waddell	Member of Board of Directors
Glenn Tilton	Member of Board of Directors
Melody Meyer	Member of Board of Directors
Rebecca Roberts	Member of Board of Directors
Robert Michael	Member of Board of Directors
Roxanne Austin	Member of Board of Directors
Thomas Freyman	Member of Board of Directors
William Burnside	Member of Board of Directors
Richard A. Gonzalez	Chairman of Managing Board
Azita Saleki-Gerhardt	Member of Executive Committee
Carrie Strom	Member of Executive Committee
Henry O. Gosebruch	Member of Executive Committee
Jeffrey R. Stewart	Member of Executive Committee
Laura J. Schumacher	Member of Executive Committee
Perry C. Siatis	Member of Executive Committee
Rae L. Livingston	Member of Executive Committee
Robert A. Michael	Member of Executive Committee
Scott T. Reents	Member of Executive Committee
Timothy J. Richmond	Member of Executive Committee